AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 MAR 4 - (NewsRx.com & NewsRx.net) -- Researchers at the Abramson Cancer Center of the University of Pennsylvania have begun a Phase I clinical trial to evaluate the effectiveness of a telomerase peptide as a possible vaccine against breast cancer.
The study will measure potential tumor-cell shrinkage in patients after an immune response has been triggered to an antigen - the telomerase peptide - found in more than 90% of breast cancer tumors.
The study is made possible through a unique $500,000 grant from the "Avon-NCI Progress for Patients" Awards program, a special private-public partnership between the Avon Foundation, Inc. and the U.S. National Cancer Institute (NCI) dedicated to accelerating early phase clinical research into promising therapies.
"This is the first clinical study to use a telomerase peptide as a possible vaccine against breast cancer," said lead researcher Robert Vonderheide, MD, DPhil, an assistant professor at the Leonard and Madlyn Abramson Family Cancer Research Institute at the University of Pennsylvania. "Our hope is that the immune response will kill the cancer and improve the health of patients."
Twenty-eight patients with metastatic breast cancer will be enrolled in the study, which is expected to last 2 years. Patients will be injected ...
Source: HighBeam Research, Immune response to telomerase tumor antigen studied as possible...